Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Werewolf Therapeutics (Nasdaq: HOWL), an innovative biopharmaceutical company focused on cancer treatments, announced that Dr. Randi Isaacs, Chief Medical Officer, will participate in a fireside chat at 9:00 AM ET on June 9, 2022, during the Jefferies Global Healthcare Conference in New York. The event is scheduled from June 8-10, 2022. A live webcast will be available, and an archived replay will be accessible for 30 days. Werewolf is pioneering therapeutics that stimulate the immune system using its proprietary PREDATOR™ platform, aiming to enhance treatment for solid tumors.

CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 9:00AM ET on June 9 during the Jefferies Global Healthcare Conference taking place June 8-10, 2022 in New York, NY.

A link to the live webcast will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 30 days following the presentation.

About Werewolf Therapeutics:
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance both WTX-124 and WTX-330 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

To learn more visit www.werewolftx.com.

Investor Contact:
Josh Rappaport
Stern IR
212.362.1200
josh.rappaport@sternir.com

Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com

Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com

FAQ

What time is Werewolf Therapeutics' presentation at the Jefferies Global Healthcare Conference?

Dr. Randi Isaacs will present at 9:00 AM ET on June 9, 2022.

Where can I watch the live webcast of Werewolf Therapeutics' presentation?

The live webcast can be accessed via the company's investor relations website.

What is the main focus of Werewolf Therapeutics?

The company focuses on developing therapeutics that activate the immune system to treat cancer.

What are the names of Werewolf Therapeutics' advanced product candidates?

The advanced product candidates are WTX-124 and WTX-330.

What is the PREDATOR™ platform used by Werewolf Therapeutics?

The PREDATOR™ platform is used to design conditionally activated molecules that stimulate the immune system.

How long will the archived replay of the fireside chat be available?

The archived replay will be available for approximately 30 days after the presentation.